Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01724671|
Recruitment Status : Unknown
Verified November 2012 by Jerome Schentag, CPL Associates.
Recruitment status was: Not yet recruiting
First Posted : November 12, 2012
Last Update Posted : November 12, 2012
|Condition or disease|
|MRSA Infection Bacteremia ABSSSI Pneumonia|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||A Case Series of Ceftaroline-treated Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline, Compared to Vancomycin-treated Patients|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Investigators will retrospectively capture patient cases that have been treated for MRSA with ceftaroline. Cases will only be included if the isolate was tested against vancomycin and ceftaroline
Investigators will retrospectively capture patient cases that were been treated for MRSA with Vancomycin.
- Bacterial Eradication [ Time Frame: 10 days ]Time to eradication of bacteria from the infection site and/or blood in relation to time to clinical improvement. For Acute Bacterial Skin and Skin Structure Infections (ABSSSI), it is recognized that wound cultures may not be repeated often, so the focus will be on the monitoring of time to clinical resolution in conjunction with time to resolve the bacteremic phase, if bacteremia is present.
- Test of Cure [ Time Frame: 10 days ]Secondary Efficacy endpoint (Cure, Failure or Indeterminate) will also be assessed at the Test of Cure, 7-10 days after last dose.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01724671
|Contact: Jerome J Schentag, Pharm.D||716-633-3330 ext email@example.com|
|Contact: Joseph Paladino, Pharm.D.||716-633-3330 ext firstname.lastname@example.org|
|United States, New York|
|Erie County Medical Center||Not yet recruiting|
|Buffalo, New York, United States, 14215|
|Contact: Joseph Paladino, Pharm.D. 716-633-3330 ext 202 email@example.com|
|Principal Investigator: Joseph Paladino, Pharm.D.|
|Principal Investigator:||Jerome J Schentag, Pharm.D.||State University at Buffalo|